Nine drugmakers working on coronavirus vaccines publicly pledged on Tuesday to prioritize safety and uphold rigorous scientific standards as concerns mount of political pressure to bring a vaccine to market before the Nov. 3 U.S. presidential election. The pledge sought to “ensure public confidence” by committing to only apply for regulatory authorization when enough data has been collected from a large phase three trial. Three vaccine manufacturers have now entered phase three trials.
The following data was compiled by Johns Hopkins University:
- Global cases: More than 27.3 million
- Global deaths: At least 893,00
- U.S. cases: More than 6.3 million
- U.S. deaths: At least 189,200
This article was originally published by Cnbc.com. Read the original article here.